JPWO2020089474A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020089474A5 JPWO2020089474A5 JP2021523957A JP2021523957A JPWO2020089474A5 JP WO2020089474 A5 JPWO2020089474 A5 JP WO2020089474A5 JP 2021523957 A JP2021523957 A JP 2021523957A JP 2021523957 A JP2021523957 A JP 2021523957A JP WO2020089474 A5 JPWO2020089474 A5 JP WO2020089474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- nucleotide sequence
- checkpoint inhibitor
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188854A JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203993.3 | 2018-11-01 | ||
| EP18203993 | 2018-11-01 | ||
| PCT/EP2019/080004 WO2020089474A1 (en) | 2018-11-01 | 2019-11-01 | Novel antagonistic anti tnfr2 antibody molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Division JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512905A JP2022512905A (ja) | 2022-02-07 |
| JPWO2020089474A5 true JPWO2020089474A5 (https=) | 2022-10-26 |
| JP2022512905A5 JP2022512905A5 (https=) | 2022-10-26 |
| JP7646542B2 JP7646542B2 (ja) | 2025-03-17 |
Family
ID=64109794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523957A Active JP7646542B2 (ja) | 2018-11-01 | 2019-11-01 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188854A Withdrawn JP2025022888A (ja) | 2018-11-01 | 2024-10-28 | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12441805B2 (https=) |
| EP (1) | EP3873936A1 (https=) |
| JP (2) | JP7646542B2 (https=) |
| KR (1) | KR20210087029A (https=) |
| CN (3) | CN118702818A (https=) |
| AU (1) | AU2019372184A1 (https=) |
| BR (1) | BR112021007995A2 (https=) |
| CA (1) | CA3117864A1 (https=) |
| IL (1) | IL282715A (https=) |
| MX (1) | MX2021005150A (https=) |
| WO (1) | WO2020089474A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023529010A (ja) | 2020-06-12 | 2023-07-06 | ナンチン リーズ バイオラブス カンパニー，リミティド | Ｔｎｆｒ２に結合する抗体およびその用途 |
| US20240043551A1 (en) * | 2020-12-11 | 2024-02-08 | Adlai Nortye Biopharma Co., Ltd. | Anti-tnfr2 antibody and application thereof |
| JP2024502035A (ja) * | 2020-12-31 | 2024-01-17 | ノヴァロック バイオセラピューティクス， リミテッド | Ｔｎｆｒ２に対する抗体およびそれの使用 |
| AU2022212842A1 (en) * | 2021-01-29 | 2023-08-31 | Shandong Simcere Biopharmaceutical Co., Ltd. | Humanized antibody against tnfr2 and use thereof |
| EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| CN119591711B (zh) * | 2024-11-12 | 2026-01-13 | 澳门大学 | 一种抑制性tnfr2单域抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
| KR20070084069A (ko) | 2004-10-08 | 2007-08-24 | 도만티스 리미티드 | Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법 |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| PL2953634T3 (pl) | 2013-02-07 | 2021-11-22 | The General Hospital Corporation | Sposoby namnażania lub zubożania limfocytów t-regulatorowych |
| DK3169341T3 (da) | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| WO2016156291A1 (en) * | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
| EP3294773A1 (en) * | 2015-05-15 | 2018-03-21 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| CN114605548A (zh) * | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| WO2017083525A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| CA3023930C (en) * | 2016-05-13 | 2025-09-23 | The General Hospital Corporation | TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| ES2941972T3 (es) * | 2016-06-22 | 2023-05-29 | Univ Paris Val De Marne | Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2 |
-
2019
- 2019-11-01 CN CN202411004492.1A patent/CN118702818A/zh active Pending
- 2019-11-01 WO PCT/EP2019/080004 patent/WO2020089474A1/en not_active Ceased
- 2019-11-01 KR KR1020217012926A patent/KR20210087029A/ko active Pending
- 2019-11-01 AU AU2019372184A patent/AU2019372184A1/en active Pending
- 2019-11-01 BR BR112021007995-5A patent/BR112021007995A2/pt unknown
- 2019-11-01 MX MX2021005150A patent/MX2021005150A/es unknown
- 2019-11-01 CA CA3117864A patent/CA3117864A1/en active Pending
- 2019-11-01 CN CN201980071097.6A patent/CN112955469B/zh active Active
- 2019-11-01 CN CN202411004493.6A patent/CN118667024A/zh active Pending
- 2019-11-01 EP EP19805901.6A patent/EP3873936A1/en active Pending
- 2019-11-01 US US17/290,352 patent/US12441805B2/en active Active
- 2019-11-01 JP JP2021523957A patent/JP7646542B2/ja active Active
-
2021
- 2021-04-27 IL IL282715A patent/IL282715A/en unknown
-
2024
- 2024-10-28 JP JP2024188854A patent/JP2025022888A/ja not_active Withdrawn
-
2025
- 2025-09-04 US US19/318,835 patent/US20250388690A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| EP3341020B1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| CA3222764A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| IL271347B2 (en) | Checkpoint inhibitor bispecific antibodies | |
| AU2016258115A1 (en) | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JPWO2019224718A5 (https=) | ||
| HK1215035A1 (zh) | 人源化抗cd134(ox40)抗體及其應用 | |
| WO2011103701A1 (zh) | 全人源抗TNF-α单克隆抗体、其制备方法及用途 | |
| CN117024592B (zh) | 抗b7h3抗体及其用途 | |
| CN113292649A (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
| JPWO2020089473A5 (https=) | ||
| KR20170138551A (ko) | Fab-dsFv 다량체 종에서 단량체 항체의 백분율을 증가시키는 방법 | |
| JP7797622B2 (ja) | ヒトインターロイキン－４受容体アルファ抗体 | |
| JPWO2020089474A5 (https=) | ||
| US20240270840A1 (en) | Antibodies against cd112r and uses thereof | |
| CN112020517A (zh) | 用于与抗pd-l1抗体组合的抗cd137抗体 | |
| RU2021115554A (ru) | Новые молекулы антагонистических анти-tnfr2-антител | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| WO2019072566A1 (en) | COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| RU2021115563A (ru) | Новые молекулы агонистических анти-tnfr2 антител | |
| TW202340254A (zh) | 抗btla抗體及其於治療癌症之用途 |